Darya-Varia Laboratoria Tbk PT

The company maintains a strong liquidity position with a current ratio of 2.45, indicating that it has sufficient short-term assets to cover its short-term liabilities. Its price-to-book ratio of 1.22 and price-to-tangible-book ratio of 1.22 suggest that the market values the company slightly above its book value, which is in line with the industry norms for pharmaceutical firms. The company's return on equity of 11.08% and return on assets of 6.98% indicate that it is generating solid returns relative to its equity and asset base. In terms of profitability, the company's operating margin is 9.69% (calculated as operating income of 216,226,307,000 divided by revenue of 2,231,748,811,000), which is a strong indicator of its ability to generate profit from its operations. This is in line with the industry's preferred metrics for profitability. The company's net profit margin of 7.35% (calculated as net income of 163,947,127,000 divided by revenue of 2,231,748,811,000) is also robust, suggesting that it is effectively managing its costs and generating a healthy bottom-line profit. The company's revenue is distributed across four segments: prescription drugs, consumer health products, export and toll manufacturing services, and services. The consumer health products segment includes skin nutrition, respiratory, vitamins, and daily relief products, while the prescription drugs segment includes products such as Daryaven, Urdafalk, and Aspilets. The company's geographic exposure is primarily within Indonesia, with a focus on domestic markets, although it also engages in export and toll manufacturing services. The company's growth trajectory is positive, with a strong revenue base of 2,231,748,811,000. While specific future revenue projections are not provided, the company's current financial performance suggests a stable and potentially growing business. The company's capital expenditure of -107,320,505,000 indicates that it is investing in its operations, which could support future growth. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of net cash being negative after subtracting total debt suggests that the company has a small amount of debt relative to its cash position, which is a positive sign for its financial stability. The company's debt-to-equity ratio of 0.0 indicates that it is not leveraging debt to finance its operations, which reduces financial risk. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company continues to operate in a stable environment, with no major disruptions reported in the latest financial data.